@article{ref1,
title="Age, neurological status MRC scale, and postoperative morbidity are prognostic factors in patients with glioblastoma treated by chemoradiotherapy",
journal="Clinical Medicine Insights: Oncology",
year="2016",
author="Verlut, C. and Mouillet, G. and Magnin, E. and Buffet-Miny, J. and Viennet, G. and Cattin, F. and Billon-Grand, N.C. and Bonnet, E. and Servagi-Vernat, S. and Godard, J. and Billon-Grand, R. and Petit, A. and Moulin, T. and Cals, L. and Pivot, X. and Curtit, E.",
volume="10",
number="",
pages="77-82",
abstract="INTRODUCTION: Temozolomide and concomitant radiotherapy followed by temozolomide has been used as a standard therapy for the treatment of newly diagnosed glioblastoma multiform since 2005. A search for prognostic factors was conducted in patients with glioblastoma routinely treated by this strategy in our institution. <br><br>METHODS: This retrospective study included all patients with histologically proven glioblastoma diagnosed between June 1, 2005, and January 1, 2012, in the Franche-Comté region and treated by radiotherapy (daily fractions of 2 Gy for a total of 60 Gy) combined with temozolomide at a dose of 75 mg/m2 per day, followed by six cycles of maintenance temozolomide (150-200 mg/m2, five consecutive days per month). The primary aim was to identify prognostic factors associated with overall survival (OS) in this cohort of patients.<br><br>RESULTS: One hundred three patients were included in this study. The median age was 64 years. The median OS was 13.7 months (95% confidence interval, 12.5-15.9 months). In multivariate analysis, age over 65 years (hazard ratio [HR] = 1.88; P = 0.01), Medical Research Council (MRC) scale 3-4 (HR = 1.62; P = 0.038), and occurrence of postoperative complications (HR = 2.15; P = 0.028) were associated with unfavorable OS.<br><br>CONCLUSIONS: This study identified three prognostic factors in patients with glioblastoma eligible to the standard chemotherapy and radiotherapy treatment. Age over 65 years, MRC scale 3-4, and occurrence of postoperative complications were associated with unfavorable OS. A simple clinical evalu-ation including these three factors enables to estimate the patient prognosis. MRC neurological scale could be a useful, quick, and simple measure to assess neurological status in glioblastoma patients. © the authors, publisher and licensee Libertas Academica Limited.<p /><p>Language: en</p>",
language="en",
issn="1179-5549",
doi="10.4137/CMO.S38474",
url="http://dx.doi.org/10.4137/CMO.S38474"
}